2 Genentech execs jump to smaller biotechs—Chutes & Ladders by Conor Hale Friday, March 22, 2019 NGM Bio gains a Genentech/Lilly vet as R&D chief; Forma nabs a Genentech commercial exec as CEO; and Nimbus builds out its biology and preclinical teams.
Celgene taps Exscientia’s AI discovery tech for 3 new programs by Amirah Al Idrus Thursday, March 21, 2019 Celgene is paying Exscientia $25 million up front in a three-year discovery deal for three programs in oncology and autoimmunity.
Nimbus adds heads of biology, development to scientific team by Amirah Al Idrus Wednesday, March 20, 2019 Nimbus promoted Jennifer Rocnik, Ph.D., to vice president of biology and Alan Collis, Ph.D., will serve as vice president of preclinical development.
Dermira soars as Dupixent challenger hits midphase endpoint by Nick Paul Taylor Monday, March 18, 2019 Dermira has generated evidence that its treatment for moderate-to-severe atopic dermatitis can pose a challenge to Regeneron and Sanofi’s Dupixent.
Sanofi CMO takes on chief digital officer role—Chutes & Ladders by Conor Hale Friday, February 15, 2019 Sanofi's CMO takes on chief digital officer role; Parexel nabs four high-profile FDA staffers; and Nimbus poaches Janssen's discovery head as CSO.
Sanofi punts 38 R&D projects to narrow pipeline focus by Nick Paul Taylor Thursday, February 7, 2019 The cull comes as Sanofi continues to increase its focus on oncology and other specialty care areas under the R&D leadership of John Reed.
Sanofi’s Darzalex rival hits primary endpoint in phase 3 by Nick Paul Taylor Tuesday, February 5, 2019 The anti-CD38 antibody prolonged progression-free survival over standard of care, providing a boost for Sanofi’s shift toward in-house programs.
Sanofi exec to head up LEO’s translational R&D—Chutes & Ladders by Conor Hale Friday, February 1, 2019 Ex-Sanofi exec to head up translational medicine at LEO Pharma; Calico brings on Amgen R&D leader to head early development; and Lonza CEO to retire.
Sanofi pays Regeneron $462M to exit I-O R&D pact by Nick Paul Taylor Monday, January 7, 2019 The move gives Sanofi the right to opt-in to two bispecific programs but otherwise leaves each company free to operate independently.
Verily pockets $1B with eyes on partnerships, M&A by Amirah Al Idrus Friday, January 4, 2019 Verily is raising $1 billion that will power new partnerships, “global business development opportunities” and potential acquisitions.
